Roth Capital analyst Boobalan Pachaiyappan initiated coverage of Immunic (IMUX) with a Buy rating and $3 price target The firm says the company has “potential best-in-indication advantages” of vidofludimus calcium in relapsing-remitting multiple sclerosis and progressive multiple sclerosis. This is validated by Immunic’s Phase 2 data that demonstrated simultaneous anti-inflammation and neuroprotection, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMUX: